ivSYTE Diagnostics
Blood-based multi-cancer early detection · Biomarker imaging AI
Series B — $125M Ask
Anchor: $40M
FDA PMA Target 2025
Key metrics
Total funding ask
$125M
Series B
Angel seed raised
$75M
Founded 2018
VC loan secured
$100M
2026 Q1
Gap to scale
$125M
Launch prep needed
Sensitivity
91%
VitaSpectra AI
Specificity
97%
Pre-clinical
Break-even
2029
Profit 2030+
Projected IRR
~34%
10-yr horizon
Business timeline & funding milestones
●
2018
Founded
$75M Angel
✓
2021 Q1
Algorithm validated
Done
$
2022
Series A
$25M
✓
2022 Q4
IDE obtained
Done
$
2024
Series A2
$50M
✓
2025 Q1
MGB partnership & pilots
Done
✓
2025 Q4
PMA obtained
Done
$
2026 Q1
VC loan
$100M
○
2028 Q2
Commercial launch & LCM
Pending
Market opportunity — Total, Serviceable & Obtainable ($B)
TAM — Total Addressable Market
SAM — Serviceable Addressable Market
SOM — Serviceable Obtainable Market
Revenue forecast vs. burn ($M)
Revenue
Burn / net loss
Competitive landscape — sensitivity vs. price
IvSYTE
Competitors
Product positioning radar
IvSYTE
Market avg
Use of proceeds — $125M Series B
R&D & clinical$45M · 36%
Compute & infra$32M · 25.6%
Headcount scale$25M · 20%
Sales & marketing$15M · 12%
G&A & legal$8M · 6.4%
Funding gap of $125M beyond VC loan required to reach commercial scale — this raise closes it.
Milestone-to-value tracker
✓
Platform technology validated✓
Clinical validation (MGB pilot)✓
Strategic partnership secured✓
PMA obtained (2025 Q4)○
Regulatory go-to-market clearance○
Commercial scale & launch (2028 Q2)○
Biomarker panel expansion